Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001
Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004
Tiotropium in COPD patients Source: Breathe 2008; 5: 271 Year: 2009
The effect of tiotropium on exacerbations and airflow in patients with COPD Source: Eur Respir J 2006; 27: 547-555 Year: 2006
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Lung function change and exacerbations in patients with COPD in the WISDOM study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Reductions in COPD Exacerbations with Tiotropium Compared to Salmeterol Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Improvement in FEV1 after acute COPD exacerbations are driven more by changes in hyperinflation than changes in proximal airway volume Source: International Congress 2015 – Clinical physiology: from airways, lung and respiratory muscles to dyspnoea in health and disease Year: 2015
Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV1 and FEV1 in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013